0001640455-18-000043.txt : 20180319 0001640455-18-000043.hdr.sgml : 20180319 20180319184203 ACCESSION NUMBER: 0001640455-18-000043 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180315 FILED AS OF DATE: 20180319 DATE AS OF CHANGE: 20180319 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Duncan Barbara Gayle CENTRAL INDEX KEY: 0001353128 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37998 FILM NUMBER: 18700185 MAIL ADDRESS: STREET 1: C/O INTERCEPT PHARMACEUTICALS, INC. STREET 2: 18 DESBROSSES STREET CITY: NEW YORK STATE: NY ZIP: 10013 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jounce Therapeutics, Inc. CENTRAL INDEX KEY: 0001640455 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 454870634 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-259-3840 MAIL ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 wf-form4_152149930973105.xml FORM 4 X0306 4 2018-03-15 0 0001640455 Jounce Therapeutics, Inc. JNCE 0001353128 Duncan Barbara Gayle C/O JOUNCE THERAPEUTICS, INC. 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2018-03-15 4 M 0 2000 4.21 A 2000 D Common Stock 2018-03-15 4 S 0 2000 28.11 D 0 D Stock Option (Right to Buy) 4.21 2018-03-15 4 M 0 2000 0 D 2026-05-09 Common Stock 2000.0 44271 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions. The option shares vest and become exercisable in 16 quarterly installments from May 10, 2016. /s/ Anna L. Barry, Attorney-in-Fact 2018-03-19